(3aR,8aS)-2-((S)-1-(Diphenylphosphanyl)piperidin-2-yl)-3a,8a-dihydro-8H-indeno[1,2-d]oxazole

Catalog No. :
ACXRZY439
CAS No. :
2757084-54-9
Molecular Formula :
C27H27N2OP
Molecular Weight :
426.5

IUPAC Name:(3aR,8aS)-2-((S)-1-(diphenylphosphaneyl)piperidin-2-yl)-3a,8a-dihydro-8H-indeno[1,2-d]oxazole

(3aR,8aS)-2-((S)-1-(Diphenylphosphanyl)piperidin-2-yl)-3a,8a-dihydro-8H-indeno[1,2-d]oxazole structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g97%$737.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(3aR,8aS)-2-((S)-1-(Diphenylphosphanyl)piperidin-2-yl)-3a,8a-dihydro-8H-indeno[1,2-d]oxazole
IUPAC Name(3aR,8aS)-2-((S)-1-(diphenylphosphaneyl)piperidin-2-yl)-3a,8a-dihydro-8H-indeno[1,2-d]oxazole
Molecular FormulaC27H27N2OP
Molecular Weight426.5
SMILES[H][C@]12N=C([C@H]3N(P(C4=CC=CC=C4)C5=CC=CC=C5)CCCC3)O[C@@]1([H])CC6=C2C=CC=C6
InChI KeyUKANMQIJWSEKCK-KKUQBAQOSA-N
Synonym(2S)-2-[(3aS,8bR)-4,8b-dihydro-3aH-indeno[1,2-d][1,3]oxazol-2-yl]piperidin-1-yl]-diphenylphosphane;8H-Indeno[1,2-d]oxazole, 2-[(2S)-1-(diphenylphosphino)-2-piperidinyl]-3a,8a-dihydro-, (3aR,8aS)-
CAS No.2757084-54-9

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H319-H413
Precautionary Statement(s)
P264-P273-P280-P305+P351+P338-P337+P313-P501

Synthetic Route by SureRoute

1. ACXRZY439 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACXRZY439 route product structure diagram
    ACXRZY4392757084-54-9
Inquiry

2. ACXRZY439 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACXRZY439 route product structure diagram
    ACXRZY4392757084-54-9
Inquiry

Comments (0)